WO2007016203A1 - Method of improving wakefulness - Google Patents
Method of improving wakefulness Download PDFInfo
- Publication number
- WO2007016203A1 WO2007016203A1 PCT/US2006/029112 US2006029112W WO2007016203A1 WO 2007016203 A1 WO2007016203 A1 WO 2007016203A1 US 2006029112 W US2006029112 W US 2006029112W WO 2007016203 A1 WO2007016203 A1 WO 2007016203A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sleep
- compound
- lower alkyl
- hydrogen
- disorder
- Prior art date
Links
- 0 C[*@](C=CCCC[n]1c(*)nc(*)c1C)C=CN* Chemical compound C[*@](C=CCCC[n]1c(*)nc(*)c1C)C=CN* 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES06774700T ES2388876T3 (en) | 2005-07-29 | 2006-07-26 | Use of [2- (2-methylimidazol-1-yl) methyl] pyridine for the treatment of sleep disorders |
NZ565763A NZ565763A (en) | 2005-07-29 | 2006-07-26 | Method of improving wakefulness |
JP2008524131A JP5017268B2 (en) | 2005-07-29 | 2006-07-26 | How to improve arousal |
CA2616177A CA2616177C (en) | 2005-07-29 | 2006-07-26 | Imidazolylalkyl-pyridines for the treatment of a sleep disorder |
US11/997,007 US20080280954A1 (en) | 2005-07-29 | 2006-07-26 | Method of Improving Wakefulness |
KR1020087002587A KR101146807B1 (en) | 2005-07-29 | 2006-07-26 | Method of improving wakefulness |
EP06774700A EP1919477B1 (en) | 2005-07-29 | 2006-07-26 | Use of [2-(2-methylimidazol-1-yl)methyl]pyridine for treating sleep disorders |
AU2006275824A AU2006275824B2 (en) | 2005-07-29 | 2006-07-26 | Method of improving wakefulness |
BRPI0614701-1A BRPI0614701A2 (en) | 2005-07-29 | 2006-07-26 | Uses of a Compound to Improve Vigilance and Pharmaceutical Compositions |
KR1020117001250A KR101187461B1 (en) | 2005-07-29 | 2006-07-26 | Method of improving wakefulness |
NO20080993A NO20080993L (en) | 2005-07-29 | 2008-02-25 | Procedure for improving inheritance |
HK08108222.5A HK1117402A1 (en) | 2005-07-29 | 2008-07-24 | Use of [2-(2-methylimidazol-1-yl)methyl]pyridine for treating sleep disorders |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70360405P | 2005-07-29 | 2005-07-29 | |
US60/703,604 | 2005-07-29 | ||
US73253605P | 2005-11-02 | 2005-11-02 | |
US60/732,536 | 2005-11-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007016203A1 true WO2007016203A1 (en) | 2007-02-08 |
Family
ID=37708941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/029112 WO2007016203A1 (en) | 2005-07-29 | 2006-07-26 | Method of improving wakefulness |
Country Status (12)
Country | Link |
---|---|
US (1) | US20080280954A1 (en) |
EP (1) | EP1919477B1 (en) |
JP (1) | JP5017268B2 (en) |
KR (2) | KR101187461B1 (en) |
AU (1) | AU2006275824B2 (en) |
BR (1) | BRPI0614701A2 (en) |
CA (1) | CA2616177C (en) |
ES (1) | ES2388876T3 (en) |
HK (1) | HK1117402A1 (en) |
NO (1) | NO20080993L (en) |
NZ (1) | NZ565763A (en) |
WO (1) | WO2007016203A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2028937A1 (en) * | 2006-05-22 | 2009-03-04 | Vanda Pharmaceuticals Inc. | Melatonin agonist treatment |
WO2009097414A1 (en) * | 2008-01-29 | 2009-08-06 | Vanda Pharmaceuticals, Inc. | Use of imidazolylalkyl-pyridines for the treatment of addictive disorders |
CN103087019A (en) * | 2013-02-06 | 2013-05-08 | 济南志合医药科技有限公司 | Preparation method of tasimelteon |
US8785492B2 (en) | 2012-01-26 | 2014-07-22 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
US8865210B2 (en) | 2006-02-13 | 2014-10-21 | Vanda Pharmaceuticals, Inc. | Stable dosage formulations of imidazolylalkyl-pyridines |
EP2861244A4 (en) * | 2012-06-14 | 2015-11-11 | Univ Michigan | Sleep apnea treatment |
US9730910B2 (en) | 2012-12-18 | 2017-08-15 | Vanda Pharmaceuticals, Inc. | Treatment of circadian rhythm disorders |
US11090285B2 (en) | 2013-11-12 | 2021-08-17 | Vanda Pharmaceuticals Inc | Treatment of circadian rhythm disorders |
US11786502B2 (en) | 2013-11-12 | 2023-10-17 | Vanda Pharmaceuticals Inc. | Method of treatment |
US11918557B2 (en) | 2012-01-26 | 2024-03-05 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0534904A1 (en) | 1991-09-23 | 1993-03-31 | Sandoz Ltd. | Imidazolylmethyl-pyridines |
US5635521A (en) * | 1991-09-23 | 1997-06-03 | Sandoz Ltd. | Imidazolylmethyl-pyridines |
WO1997032871A1 (en) | 1996-03-08 | 1997-09-12 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
US20010034373A1 (en) | 2000-02-09 | 2001-10-25 | Matthew Miller | Low dose modafinil for enhancement of cognitive function |
WO2001078726A1 (en) | 2000-04-13 | 2001-10-25 | Novartis Ag | New uses of imidazolylmethyl-pyridines |
US20040143021A1 (en) | 2003-01-21 | 2004-07-22 | Larijani Ghassem E. | Compositions and methods for improving recovery after general anesthesia |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2593809B1 (en) * | 1986-01-31 | 1988-07-22 | Lafon Labor | BENZHYDRYLSULFINYLACETAMIDE, PROCESS FOR PREPARATION AND THERAPEUTIC USE |
US20040048931A1 (en) * | 2002-07-12 | 2004-03-11 | Craig Heacock | Modafinil pharmaceutical compositions |
-
2006
- 2006-07-26 KR KR1020117001250A patent/KR101187461B1/en not_active IP Right Cessation
- 2006-07-26 ES ES06774700T patent/ES2388876T3/en active Active
- 2006-07-26 US US11/997,007 patent/US20080280954A1/en not_active Abandoned
- 2006-07-26 BR BRPI0614701-1A patent/BRPI0614701A2/en not_active IP Right Cessation
- 2006-07-26 WO PCT/US2006/029112 patent/WO2007016203A1/en active Application Filing
- 2006-07-26 AU AU2006275824A patent/AU2006275824B2/en not_active Ceased
- 2006-07-26 NZ NZ565763A patent/NZ565763A/en not_active IP Right Cessation
- 2006-07-26 JP JP2008524131A patent/JP5017268B2/en not_active Expired - Fee Related
- 2006-07-26 CA CA2616177A patent/CA2616177C/en not_active Expired - Fee Related
- 2006-07-26 KR KR1020087002587A patent/KR101146807B1/en not_active IP Right Cessation
- 2006-07-26 EP EP06774700A patent/EP1919477B1/en active Active
-
2008
- 2008-02-25 NO NO20080993A patent/NO20080993L/en not_active Application Discontinuation
- 2008-07-24 HK HK08108222.5A patent/HK1117402A1/en not_active IP Right Cessation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0534904A1 (en) | 1991-09-23 | 1993-03-31 | Sandoz Ltd. | Imidazolylmethyl-pyridines |
US5635521A (en) * | 1991-09-23 | 1997-06-03 | Sandoz Ltd. | Imidazolylmethyl-pyridines |
US5856343A (en) | 1991-09-23 | 1999-01-05 | Novartis Ag | Imidazolylmethyl-pyridines used for senile dementia |
WO1997032871A1 (en) | 1996-03-08 | 1997-09-12 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
US20010034373A1 (en) | 2000-02-09 | 2001-10-25 | Matthew Miller | Low dose modafinil for enhancement of cognitive function |
WO2001078726A1 (en) | 2000-04-13 | 2001-10-25 | Novartis Ag | New uses of imidazolylmethyl-pyridines |
US20040143021A1 (en) | 2003-01-21 | 2004-07-22 | Larijani Ghassem E. | Compositions and methods for improving recovery after general anesthesia |
Non-Patent Citations (4)
Title |
---|
BERESFORD ET AL., J. PHARMACOL. AND EXP. THERAPEUTICS, vol. 285, 1998, pages 1239 - 45 |
See also references of EP1919477A4 * |
VACHHARAJANI ET AL., J. PHARMACEUTICAL SCI., vol. 92, no. 4, pages 760 - 772 |
VACHHARAJANI N.N. ET AL.: "Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 92, no. 4, April 2003 (2003-04-01), pages 760 - 772, XP008074135 * |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8865210B2 (en) | 2006-02-13 | 2014-10-21 | Vanda Pharmaceuticals, Inc. | Stable dosage formulations of imidazolylalkyl-pyridines |
EP2028937A4 (en) * | 2006-05-22 | 2010-06-02 | Vanda Pharmaceuticals Inc | Melatonin agonist treatment |
EP2028937A1 (en) * | 2006-05-22 | 2009-03-04 | Vanda Pharmaceuticals Inc. | Melatonin agonist treatment |
WO2009097414A1 (en) * | 2008-01-29 | 2009-08-06 | Vanda Pharmaceuticals, Inc. | Use of imidazolylalkyl-pyridines for the treatment of addictive disorders |
US10149829B2 (en) | 2012-01-26 | 2018-12-11 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
US9855241B2 (en) | 2012-01-26 | 2018-01-02 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
US11918556B2 (en) | 2012-01-26 | 2024-03-05 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
US9060995B2 (en) | 2012-01-26 | 2015-06-23 | Vanda Pharmaceuticals, Inc. | Treatment of circadian rhythm disorders |
US11833130B2 (en) | 2012-01-26 | 2023-12-05 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
US9539234B2 (en) | 2012-01-26 | 2017-01-10 | Vanda Pharmaceuticals, Inc. | Treatment of circadian rhythm disorders |
US9549913B2 (en) | 2012-01-26 | 2017-01-24 | Vanda Pharmaceuticals, Inc. | Treatment of circadian rhythm disorders |
US8785492B2 (en) | 2012-01-26 | 2014-07-22 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
USRE46604E1 (en) | 2012-01-26 | 2017-11-14 | Vanda Pharmaceuticals, Inc. | Treatment of circadian rhythm disorders |
US11826339B2 (en) | 2012-01-26 | 2023-11-28 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
US11918557B2 (en) | 2012-01-26 | 2024-03-05 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
US11633377B2 (en) | 2012-01-26 | 2023-04-25 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
US10449176B2 (en) | 2012-01-26 | 2019-10-22 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
US10610510B2 (en) | 2012-01-26 | 2020-04-07 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
US10945988B2 (en) | 2012-01-26 | 2021-03-16 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
US11850229B2 (en) | 2012-01-26 | 2023-12-26 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
US11285129B2 (en) | 2012-01-26 | 2022-03-29 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
US11224584B2 (en) | 2012-06-14 | 2022-01-18 | The Regents Of The University Of Michigan | Sleep apnea treatment |
US10172920B2 (en) | 2012-06-14 | 2019-01-08 | The Regents Of The University Of Michigan | Sleep apnea treatment |
EP2861244A4 (en) * | 2012-06-14 | 2015-11-11 | Univ Michigan | Sleep apnea treatment |
US9730910B2 (en) | 2012-12-18 | 2017-08-15 | Vanda Pharmaceuticals, Inc. | Treatment of circadian rhythm disorders |
CN103087019A (en) * | 2013-02-06 | 2013-05-08 | 济南志合医药科技有限公司 | Preparation method of tasimelteon |
CN103087019B (en) * | 2013-02-06 | 2015-02-04 | 济南志合医药科技有限公司 | Preparation method of tasimelteon |
US11786502B2 (en) | 2013-11-12 | 2023-10-17 | Vanda Pharmaceuticals Inc. | Method of treatment |
US11090285B2 (en) | 2013-11-12 | 2021-08-17 | Vanda Pharmaceuticals Inc | Treatment of circadian rhythm disorders |
Also Published As
Publication number | Publication date |
---|---|
US20080280954A1 (en) | 2008-11-13 |
JP2009502945A (en) | 2009-01-29 |
KR101146807B1 (en) | 2012-05-21 |
KR101187461B1 (en) | 2012-10-02 |
EP1919477A4 (en) | 2009-03-18 |
CA2616177A1 (en) | 2007-02-08 |
JP5017268B2 (en) | 2012-09-05 |
AU2006275824B2 (en) | 2010-12-16 |
KR20080033322A (en) | 2008-04-16 |
EP1919477A1 (en) | 2008-05-14 |
EP1919477B1 (en) | 2012-07-11 |
CA2616177C (en) | 2012-05-01 |
KR20110011748A (en) | 2011-02-08 |
BRPI0614701A2 (en) | 2011-04-12 |
HK1117402A1 (en) | 2009-01-16 |
NZ565763A (en) | 2010-12-24 |
ES2388876T3 (en) | 2012-10-19 |
NO20080993L (en) | 2008-02-25 |
AU2006275824A1 (en) | 2007-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2616177C (en) | Imidazolylalkyl-pyridines for the treatment of a sleep disorder | |
TWI419681B (en) | Use of carbamate compounds for the manufacturing of a medicament for treating excessive daytime sleeping(eds) | |
RU2395504C2 (en) | Alpha-aminoamide derivatives used for treating lower urinary tract disorders | |
KR20160097366A (en) | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS(SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS | |
EP1832286A1 (en) | Preventive or therapeutic agent for sleep disorder | |
Jiang et al. | Lithium affects rat hippocampal electrophysiology and epileptic seizures in a dose dependent manner | |
JPWO2012033070A1 (en) | Pain treatment | |
TW202035415A (en) | Compound for treating osteoarthritis | |
JP2013514379A (en) | Compounds for the treatment of neurological disorders | |
CA3033039C (en) | Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors | |
MX2008001249A (en) | Method of improving wakefulness | |
CA3033050A1 (en) | Triple combination of histamine-3 receptor inverse agonists, acetylcholinesterase inhibitors and nmda receptor antagonist | |
JP2006143707A (en) | Therapeutic agent for neurological disease | |
CN101242836A (en) | Method of improving wakefulness | |
US20200368310A1 (en) | Treatment with nmda receptor modulators | |
CN111840300A (en) | Pharmaceutical composition and use for treating mental disorders and pain associated with nerve damage | |
MXPA06008188A (en) | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680030387.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2616177 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/001249 Country of ref document: MX Ref document number: 12008500230 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11997007 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008524131 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087002587 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006275824 Country of ref document: AU Ref document number: 565763 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 978/CHENP/2008 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2006275824 Country of ref document: AU Date of ref document: 20060726 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006774700 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020117001250 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0614701 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080129 |